志海 秦;Günther Richter;Thomas Schüler;Sabrina Ibe;雪涛 曹;Thomas Blankenstein
China Association for Science and Technology;Max Delbrück Center for Molecular Medicine in the Helmholtz Association
发表时间:1998-5
期 刊:Nature Medicine
语 言:English
U R L: http://www.scopus.com/inward/record.url?scp=0031863680&partnerID=8YFLogxK
Cytotoxic T lymphocyte (CTL) mediated tumor immunity against major histocompatibility antigen (MHC) class I-positive but class II-negative tumors often requires help from CD4+ T cells. These CD4 cells are activated by MHC class II-positive cells that present tumor derived antigens. Considering that different antigen presenting cells, such as B cells, macrophages and dendritic cells compete for antigen and influence the outcome of an immune response, we analyzed tumor immunity in B cell- deficient mice. These mice appear normal with regard to T celt immunity and tolerance to some pure foreign antigens. We show here that the low immunogenicity of tumors is caused by B cells whose presence in the priming phase results in disabled CD4+ T cell help for CTL mediated tumor immunity. Instead, in the presence of B cells, a non-protective humoral immune response is induced. Our results may explain the enigmatic observation that tumor-reactive antibodies occur frequently in cancer patients.
Scopus度量
年份 | CiteScore | SJR | SNIP |
---|---|---|---|
1996 | |||
1997 | |||
1998 | |||
1999 | 8.926 | 5.615 | |
2000 | 8.092 | 5.633 | |
2001 | 7.861 | 5.329 | |
2002 | 7.884 | 5.216 | |
2003 | 9.288 | 5.288 | |
2004 | 10.042 | 5.465 | |
2005 | 10.215 | 5.584 | |
2006 | 10.345 | 5.811 | |
2007 | 8.955 | 5.458 | |
2008 | 9.064 | 5.065 | |
2009 | 9.122 | 5.879 | |
2010 | 10.376 | 5.6 | |
2011 | 29 | 9.808 | 5.275 |
2012 | 27.2 | 8.525 | 4.61 |
2013 | 26.1 | 9.439 | 4.597 |
2014 | 31.2 | 10.146 | 4.729 |
2015 | 38.5 | 12.642 | 5.087 |
2016 | 41.2 | 14.994 | 5.549 |
2017 | 47.5 | 17.067 | 5.578 |
2018 | 48.3 | 17.007 | 6.128 |
2019 | 45.9 | 15.812 | 5.802 |
2020 | 62.4 | 19.536 | 7.912 |
2021 | 72 |
相似文献推荐